查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球癌症诊断市场评估：按产品类型、技术、癌症类型、最终用户、地区、机会、预测（2016-2030）
市场调查报告书
商品编码
1394581

全球癌症诊断市场评估：按产品类型、技术、癌症类型、最终用户、地区、机会、预测（2016-2030）

Cancer Diagnostics Market Assessment, By Product, By Technology, By Cancer Type, By End-user, By Region, Opportunities and Forecast, 2016-2030F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 206 Pages | 商品交期: 3-5个工作天内

价格

全球癌症诊断市场规模预计将从 2022 年的 1,475 亿美元增至 2030 年的 2,386.6 亿美元，2023-2030 年预测期间复合年增长率为 6.2%。Masu。 由于全球癌症患者数量不断增加，预计该市场将大幅成长。 癌症发生率的快速增加可归因于遗传变异、饮酒和吸烟、荷尔蒙和生活方式的改变、致癌微生物感染以及污染增加，这些因素在推动癌症诊断市场的重要因素中发挥作用。 诊断中心数量的增加也是全球癌症诊断市场的驱动因素。 这将有助于增加癌症筛检，从而带来更好的结果。 人工智慧和机器学习等技术在癌症诊断和预测中的结合正在推动癌症诊断市场的成长。 此外，扩大产业联盟、创新和先进产品的推出以及政府促进癌症筛检的措施预计将在预测期内推动市场成长。 然而，与癌症诊断程序相关的高成本以及缺乏熟练的专业人员进行癌症筛检可能会阻碍市场成长。

2023 年 7 月，诊断资讯服务先驱 Quest Diagnostics 宣布透过其专业病理学公司 AmeriPath 与 Envision Sciences 合作推出新的前列腺癌生物标记测试。 这项新的基于组织的检测服务旨在帮助满足临床对诊断的迫切需求，该诊断可以区分男性前列腺癌的侵袭性和非侵袭性病例。 生物标记测试的前沿发展预计将在推动癌症诊断市场方面发挥关键作用。

癌症病人增加

无论是在已开发国家或发展中国家，癌症都是全球主要死亡原因之一。 近年来，生活习惯、烟酒摄取、辐射暴露等发生了显着变化，这些都是癌症的主要原因。 由于这些因素，癌症患者的数量正在迅速增加。 早期检测癌症以进行有效治疗的诊断技术的进步正在推动癌症诊断市场的需求。 在这种情况下，癌症筛检对于降低相关死亡率非常重要，从而进一步促进全球癌症诊断市场的成长。

根据世界卫生组织（WHO）的数据，2020年新诊断癌症患者人数为19,292,789人，预计到2025年将增至21,618,445人，增长率为12.1%。 截至2020年底，过去五年已有780万名女性被诊断出罹患乳癌，使其成为世界上最常见的癌症。

诊断中心数量增加

随着癌症患者数量的日益增加，对癌症筛检的需求也在不断增加，并且由于发展中国家公共医疗设施中可用的诊断成像技术有限，许多私人诊断中心正在扩大我们的分支机构。 除了私人诊断设施外，还建立了政府资助的诊断实验室以促进癌症筛检。 市场进入者正在与现有组织合作建立或翻新癌症诊断设施。 此外，各种诊断公司正在不同地区扩大业务。 因此，诊断中心的增加预计将推动市场成长。

例如，2023 年 3 月，克利夫兰诊所最先进的癌症设施法蒂玛·宾特·穆巴拉克中心在阿布扎比克利夫兰诊所开业。 新的癌症医院将为阿联酋和中东地区的癌症诊断和治疗提供全面和创新的方法。 由于新诊所，患者将不再需要飞往海外才能接受基本护理和治疗。 Fatima bint Mubarak 中心拥有诊断设施、24 个用于静脉注射药物的私人房间以及 32 个用于多学科癌症检查的检查室。

本报告研究和分析了全球癌症诊断市场，提供市场规模和预测、市场动态以及主要参与者的现状和前景。

目录

第一章研究方法

第 2 章专案范围与定义

第 3 章 COVID-19 对全球癌症诊断市场的影响

第 4 章执行摘要

第五章全球癌症诊断市场展望（2016-2030）

  • 市场规模与预测
    • 金额
    • 数量
  • 按产品
    • 消耗品
    • 设备
    • 服务
  • 按技术
    • 体外诊断测试
    • 影像诊断
    • 切片技术
    • 其他
  • 依癌症类型
    • 乳癌
    • 肺癌
    • 大肠癌
    • 黑色素瘤
    • 血癌
    • 摄护腺癌
    • 卵巢癌
    • 胃癌
    • 肝癌
    • 其他癌症
  • 按最终用户
    • 医院
    • 诊断实验室
    • 影像诊断中心
    • 癌症研究所
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 市占率：依公司划分（2022 年）

第六章全球癌症诊断市场展望（2016-2030）

  • 北美
    • 按产品
    • 按技术
    • 依癌症类型
    • 按最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 南美洲
    • 巴西
    • 阿根廷
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印尼
    • 菲律宾
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非

第 7 章市场地图（2022 年）

  • 按产品
  • 按技术
  • 依癌症类型
  • 按最终用户
  • 按地区

第八章宏观环境与产业结构

  • 需求与供给分析
  • 进出口分析 - 数量与价值
  • 供应/价值链分析
  • PESTEL 分析
  • 波特五力分析

第 9 章市场动态

  • 生长促进因素
  • 抑製成长的因素（问题、限制因素）

第 10 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/最新技术

第十一章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析（2022 年）
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家公司进入市场）
  • 专利分析（如果适用）

第十二章价格分析

第 13 章案例研究

第14章主要公司展望

  • Abbott
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • QIAGEN
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • Quest Diagnostics Incorporated
  • Merck KGaA
  • Hologic, Inc.
  • Becton, Dickinson and Company

第 15 章策略建议

第16章关于我们公司，免责声明

Product Code: MX10732

The Global cancer diagnostics market size was valued at USD 147.5 billion in 2022 and is expected to reach USD 238.66 billion in 2030 with a CAGR of 6.2% for the forecast period between 2023 and 2030F. As per WHO, cancer is the second leading cause of death around the world. Healthcare professionals and market players are focused on developing more advanced solutions for early cancer diagnosis to reduce the cancer burden. Cancer screening is performed through several techniques depending on the site and type of cancer. The global cancer diagnostics market is expected to grow exponentially due to the increasing number of cancer cases around the world. The surge in the prevalence of cancer can be attributed to inherited mutations, alcohol and tobacco consumption, hormonal and lifestyle changes, carcinogenic microbial infections, and increasing pollution, which play an important role in driving the cancer diagnostics market. Growth in the number of diagnostic centers is also a driving force for the global cancer diagnostics market. It promotes a high number of cancer screenings leading to better outcomes. The inclusion of technologies like artificial intelligence, and machine learning, for the diagnosis and prediction of cancer is driving the growth in the cancer diagnostics market. Additionally, growing industry collaborations, innovative and advanced product launches, and government initiatives to boost cancer screening are anticipated to drive market growth during the forecast period. However, the high costs associated with cancer diagnostic procedures and lack of skilled professionals to perform cancer screenings may hinder market growth.

In July 2023, the pioneer in diagnostic information services, Quest Diagnostics, announced the introduction of a new prostate cancer biomarker test via its subspecialty pathology company, AmeriPath, in association with Envision Sciences. The goal of the new tissue-based test service is to assist in meeting the urgent clinical demand for diagnostics that can distinguish between aggressive and less aggressive cases of prostate cancer in men. Cutting-edge developments in biomarker tests are expected to play a significant role in driving the cancer diagnostics market.

Increasing Number of Cancer Patients

Cancer is one of the leading causes of death globally, without any exception in developed or developing countries. In recent years, a notable change in lifestyle, tobacco and alcohol consumption, and radiation exposure, has been observed which are the leading causes of cancer. Due to these factors, the number of cancer cases has increased drastically. Diagnostic advancement for early detection when cancer can be effectively treated increases the demand in the cancer diagnostics market. Cancer screening becomes crucial in this scenario to reduce associated mortality, further boosting the growth of the global cancer diagnostics market.

As per the World Health Organization, there were 19,292,789 newly diagnosed cancer cases in 2020 which is expected to increase to 21,618,445 with a growth rate of 12.1% by 2025. By 2020-year end, there were 7.8 million women alive who were diagnosed with breast cancer in the past five years, making it the world's most prevalent cancer.

Growth in the Number of Diagnostic Centers

As the number of cancer cases is increasing day by day, the demand for cancer screening is also increasing, and due to limited imaging techniques available at public healthcare facilities in developing countries, numerous private diagnostic centers are expanding their branches. Besides private diagnostic establishments, government-funded diagnostic laboratories are also being established to facilitate cancer screening. The market players collaborate with existing organizations to establish or revamp cancer diagnostic facilities. Various diagnostic companies are also expanding their businesses across different geographies. Thus, growth in the number of diagnostic centers is expected to drive growth in the market.

For instance, in March 2023, The Fatima bint Mubarak Center, a brand-new, cutting-edge cancer facility from Cleveland Clinic, opened at Cleveland Clinic Abu Dhabi. In the United Arab Emirates and the Middle East, the new cancer hospital offers a comprehensive and revolutionary approach to cancer diagnosis and treatment. Patients won't have to fly overseas to receive the essential care and treatment, thanks to the new clinic. The Fatima bint Mubarak Center features diagnostic facilities, 24 private infusion rooms for intravenous medicine administration, and 32 exam rooms for multidisciplinary cancer consultations.

Government Initiatives

Cancer diagnostics research and development of screening tests and products is quite an extensive process that requires a lot of funding. The funding for cancer screening research mainly comes from market players as well as government authorities. In the global cancer diagnostics market, government organizations, associations, and agencies actively promote cancer screening and treatments by providing research funds and driving awareness initiatives, thereby fostering market growth. Additionally, government policies supporting the manufacturing and distribution of cancer diagnostic products are also driving growth in the global cancer diagnostics market.

For instance, according to a press release from The White House, in March 2023, the United States government invested 394.5 million USD in National Comprehensive Cancer Control Program, which includes the Cancer Genomics Program, the National Breast and Cervical Cancer Early Detection Programs to improve various cancer screening and diagnostic services for uninsured and underinsured American women, and the Colorectal Cancer Control Program to increase colorectal cancer screening rates among people age 45 to 75.

In January 2023, the United Kingdom government announced a 10-million-euro investment to develop 29 new breast cancer screening units, these units will be dedicated to reducing the breast cancer burden of the UK. Such government support initiatives and funding for breast cancer research, diagnosis, and treatment are anticipated to drive market growth for the global cancer diagnostics market.

Technological Advancements

The rapid growth of this sector can be attributed to the strong inclination of physicians towards in-vitro diagnostics products for cancer diagnosis. Significant progress has been made in the global market for cancer diagnostics, revolutionizing the detection and treatment of cancer. Advancements in liquid biopsies, next-generation sequencing technology, and molecular diagnostics have enhanced individualized therapy methods and early detection. Targeted medicines, improved patient outcomes, and fewer side effects have been made possible by biomarker identification and accompanied diagnostic testing. Furthermore, the utilization of artificial intelligence and machine learning algorithms has proven to be crucial in analyzing intricate data, enabling more precise diagnosis, and forecasting of treatment outcomes. Ongoing developments in oncology within the field of in vitro diagnostics are revolutionizing cancer care and providing fresh hope in the fight against cancer. Additionally, the segment's expansion is projected to gain momentum due to the growing number of breast cancer patients worldwide.

For instance, in November 2022, Google Health announced a financial agreement with iCAD (a leading market player focused on cancer detection and medical technology development). Through this partnership, iCAD can incorporate Google Health's mammography AI research model in its products for clinical usage. This advancement will help in better and more precise diagnosis of breast cancers.

Impact of COVID-19

Different aspects of healthcare were affected by COVID-19. The global market for cancer diagnostics experienced a notable decline as a result of government-imposed lockdowns and preventive measures across the globe. The market witnessed a reduction in cancer screening.

In addition, several elective examinations, operations, and treatments were canceled or postponed because of preventive restrictions for COVID-19. A report that was published in SAGE in June 2022 states that there was a 44% drop in screening mammography for breast cancer between 2019 and 2020. Despite the COVID-19 pandemic's effects, telehealth initiatives and the application of AI and machine learning gave rise to opportunities for several digital businesses to produce cutting-edge solutions for early cancer detection and prediction. Thus, the overall COVID-19 pandemic negatively affected the screening and treatment rate of cancer but also contributed to technological advancements.

Key Players Landscape and Outlook

Market players have employed a range of strategies to increase the range of solutions they offer and give the customers access to a wide range of innovative and cutting-edge products. Additionally, companies are expanding the range of diagnostic services they offer to capture a bigger portion of the market. Many major industry players are using both different growth techniques, like partnerships, mergers and acquisitions; and the development and launch of new products, to strengthen their position in the global market.

In June 2022, Roche announced the release of its newest cutting-edge tissue staining platform, the BenchMark ULTRA PLUS system, for doctors to decide on a patient's course of therapy in a timely manner, the system provides rapid and accurate test results. Several innovations are included in the new system, including an integrated touchscreen for an enhanced user experience, new intuitive software, remote monitoring capabilities, and more environmentally friendly product packaging and waste management.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on the Global Cancer Diagnostics Market

4. Executive Summary

5. Global Cancer Diagnostics Market Outlook, 2016-2030F

  • 5.1 Market Size & Forecast
    • 5.1.1 By Value
    • 5.1.2 By Volume
  • 5.2 By Product
    • 5.2.1 Consumables
      • 5.2.1.1 Antibodies
      • 5.2.1.2 Kits and Reagents
      • 5.2.1.3 Probes
      • 5.2.1.4 Other Consumables
    • 5.2.2 Instruments
      • 5.2.2.1 Pathology-based Instruments
      • 5.2.2.1.1 Slide Staining Systems
      • 5.2.2.1.2 Tissue Processing Systems
      • 5.2.2.1.3 Cell Processors
      • 5.2.2.1.4 PCR Instruments
      • 5.2.2.1.5 NGS Instruments
      • 5.2.2.1.6 Microarrays
      • 5.2.2.1.7 Other Pathology-based Instruments
      • 5.2.2.2 Imaging Instruments
      • 5.2.2.2.1 CT Instruments
      • 5.2.2.2.2 Ultrasound Instruments
      • 5.2.2.2.3 MRI Instruments
      • 5.2.2.2.4 PET Scan Instruments
      • 5.2.2.2.5 Mammography Instruments
      • 5.2.2.2.6 Other Nuclear Imaging Instruments
      • 5.2.2.3 Biopsy Instruments
      • 5.2.2.4 Other Instruments
    • 5.2.3 Services
  • 5.3 By Technology
    • 5.3.1 In-vitro Diagnostic Testing
      • 5.3.1.1 Polymerase Chain Reaction (PCR)
      • 5.3.1.2 Blood Test
      • 5.3.1.3 In-situ Hybridization (ISH)
      • 5.3.1.4 Immunohistochemistry
      • 5.3.1.5 Next-generation Sequencing (NGS)
      • 5.3.1.6 Microarrays
      • 5.3.1.7 Flow Cytometry
      • 5.3.1.8 Immunoassays
      • 5.3.1.9 Other In-vitro Diagnostic Testing Technologies
    • 5.3.2 Imaging
      • 5.3.2.1 Magnetic Resonance Imaging (MRI)
      • 5.3.2.2 Computed Tomography (CT)
      • 5.3.2.3 Positron Emission Tomography (PET)
      • 5.3.2.4 Mammography
      • 5.3.2.5 Ultrasound
    • 5.3.3 Biopsy Technologies
    • 5.3.4 Other
  • 5.4 By Cancer Type
    • 5.4.1 Breast Cancer
    • 5.4.2 Lung Cancer
    • 5.4.3 Colorectal Cancer
    • 5.4.4 Melanoma
    • 5.4.5 Blood Cancer
    • 5.4.6 Prostate Cancer
    • 5.4.7 Ovarian Cancer
    • 5.4.8 Stomach Cancer
    • 5.4.9 Liver Cancer
    • 5.4.10 Other Cancer
  • 5.5 By End-user
    • 5.5.1 Hospitals
    • 5.5.2 Diagnostic Laboratories
    • 5.5.3 Diagnostic Imaging Centers
    • 5.5.4 Cancer Research Institutes
    • 5.5.5 Others
  • 5.6 By Region
    • 5.6.1 North America
    • 5.6.2 Europe
    • 5.6.3 Asia Pacific
    • 5.6.4 South America
    • 5.6.5 Middle East & Africa
  • 5.7 By Company Market Share (%), 2022

6. Global Ventilator Market Outlook, 2016-2030F

  • 6.1. North America
    • 6.1.1. By Product
      • 6.1.1.1. Consumables
      • 6.1.1.1.1. Antibodies
      • 6.1.1.1.2. Kits and Reagents
      • 6.1.1.1.3. Probes
      • 6.1.1.1.4. Other Consumables
      • 6.1.1.2. Instruments
      • 6.1.1.2.1. Pathology-based Instruments
      • 6.1.1.2.1.1. Slide Staining Systems
      • 6.1.1.2.1.2. Tissue Processing Systems
      • 6.1.1.2.1.3. Cell Processors
      • 6.1.1.2.1.4. PCR Instruments
      • 6.1.1.2.1.5. NGS Instruments
      • 6.1.1.2.1.6. Microarrays
      • 6.1.1.2.1.7. Other Pathology-based Instruments
      • 6.1.1.2.2. Imaging Instruments
      • 6.1.1.2.2.1. CT Instruments
      • 6.1.1.2.2.2. Ultrasound Instruments
      • 6.1.1.2.2.3. MRI Instruments
      • 6.1.1.2.2.4. PET Scan Instruments
      • 6.1.1.2.2.5. Mammography Instruments
      • 6.1.1.2.2.6. Other Nuclear Imaging Instruments
      • 6.1.1.2.3. Biopsy Instruments
      • 6.1.1.2.4. Other Instruments
      • 6.1.1.3. Services
    • 6.1.2. By Technology
      • 6.1.2.1. In-vitro Diagnostic Testing
      • 6.1.2.1.1. Polymerase Chain Reaction (PCR)
      • 6.1.2.1.2. Blood Test
      • 6.1.2.1.3. In-situ Hybridization (ISH)
      • 6.1.2.1.4. Immunohistochemistry
      • 6.1.2.1.5. Next-generation Sequencing (NGS)
      • 6.1.2.1.6. Microarrays
      • 6.1.2.1.7. Flow Cytometry
      • 6.1.2.1.8. Immunoassays
      • 6.1.2.1.9. Other In-vitro Diagnostic Testing Technologies
      • 6.1.2.2. Imaging
      • 6.1.2.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.2.2.2. Computed Tomography (CT)
      • 6.1.2.2.3. Positron Emission Tomography (PET)
      • 6.1.2.2.4. Mammography
      • 6.1.2.2.5. Ultrasound
      • 6.1.2.3. Biopsy Technologies
      • 6.1.2.4. Other
    • 6.1.3. By Cancer Type
      • 6.1.3.1. Breast Cancer
      • 6.1.3.2. Lung Cancer
      • 6.1.3.3. Colorectal Cancer
      • 6.1.3.4. Melanoma
      • 6.1.3.5. Blood Cancer
      • 6.1.3.6. Prostate Cancer
      • 6.1.3.7. Ovarian Cancer
      • 6.1.3.8. Stomach Cancer
      • 6.1.3.9. Liver Cancer
      • 6.1.3.10. Other Cancer
    • 6.1.4. By End-user
      • 6.1.4.1. Hospitals
      • 6.1.4.2. Diagnostic Laboratories
      • 6.1.4.3. Diagnostic Imaging Centers
      • 6.1.4.4. Cancer Research Institutes
      • 6.1.4.5. Others
    • 6.1.5. United States*
      • 6.1.5.1. By Product
      • 6.1.5.1.1. Consumables
      • 6.1.5.1.1.1. Antibodies
      • 6.1.5.1.1.2. Kits and Reagents
      • 6.1.5.1.1.3. Probes
      • 6.1.5.1.1.4. Other Consumables
      • 6.1.5.1.2. Instruments
      • 6.1.5.1.2.1. Pathology-based Instruments
      • 6.1.5.1.2.1.1. Slide Staining Systems
      • 6.1.5.1.2.1.2. Tissue Processing Systems
      • 6.1.5.1.2.1.3. Cell Processors
      • 6.1.5.1.2.1.4. PCR Instruments
      • 6.1.5.1.2.1.5. NGS Instruments
      • 6.1.5.1.2.1.6. Microarrays
      • 6.1.5.1.2.1.7. Other Pathology-based Instruments
      • 6.1.5.1.2.2. Imaging Instruments
      • 6.1.5.1.2.2.1. CT Instruments
      • 6.1.5.1.2.2.2. Ultrasound Instruments
      • 6.1.5.1.2.2.3. MRI Instruments
      • 6.1.5.1.2.2.4. PET Scan Instruments
      • 6.1.5.1.2.2.5. Mammography Instruments
      • 6.1.5.1.2.2.6. Other Nuclear Imaging Instruments
      • 6.1.5.1.2.3. Biopsy Instruments
      • 6.1.5.1.2.4. Other Instruments
      • 6.1.5.1.3. Services
      • 6.1.5.2. By Technology
      • 6.1.5.2.1. In-vitro Diagnostic Testing
      • 6.1.5.2.1.1. Polymerase Chain Reaction (PCR)
      • 6.1.5.2.1.2. Blood Test
      • 6.1.5.2.1.3. In-situ Hybridization (ISH)
      • 6.1.5.2.1.4. Immunohistochemistry
      • 6.1.5.2.1.5. Next-generation Sequencing (NGS)
      • 6.1.5.2.1.6. Microarrays
      • 6.1.5.2.1.7. Flow Cytometry
      • 6.1.5.2.1.8. Immunoassays
      • 6.1.5.2.1.9. Other In-vitro Diagnostic Testing Technologies
      • 6.1.5.2.2. Imaging
      • 6.1.5.2.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.5.2.2.2. Computed Tomography (CT)
      • 6.1.5.2.2.3. Positron Emission Tomography (PET)
      • 6.1.5.2.2.4. Mammography
      • 6.1.5.2.2.5. Ultrasound
      • 6.1.5.2.3. Biopsy Technologies
      • 6.1.5.2.4. Other
      • 6.1.5.3. By Cancer Type
      • 6.1.5.3.1. Breast Cancer
      • 6.1.5.3.2. Lung Cancer
      • 6.1.5.3.3. Colorectal Cancer
      • 6.1.5.3.4. Melanoma
      • 6.1.5.3.5. Blood Cancer
      • 6.1.5.3.6. Prostate Cancer
      • 6.1.5.3.7. Ovarian Cancer
      • 6.1.5.3.8. Stomach Cancer
      • 6.1.5.3.9. Liver Cancer
      • 6.1.5.3.10. Other Cancer
      • 6.1.5.4. By End-user
      • 6.1.5.4.1. Hospitals
      • 6.1.5.4.2. Diagnostic Laboratories
      • 6.1.5.4.3. Diagnostic Imaging Centers
      • 6.1.5.4.4. Cancer Research Institutes
      • 6.1.5.4.5. Others
    • 6.1.6. Canada
    • 6.1.7. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2022

  • 7.1. By Product
  • 7.2. By Technology
  • 7.3. By Cancer Type
  • 7.4. By End-user
  • 7.5. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Abbott
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Thermo Fisher Scientific Inc.
  • 14.3. Illumina, Inc.
  • 14.4. QIAGEN
  • 14.5. F. Hoffmann-La Roche Ltd
  • 14.6. Agilent Technologies, Inc.
  • 14.7. Quest Diagnostics Incorporated
  • 14.8. Merck KGaA
  • 14.9. Hologic, Inc.
  • 14.10. Becton, Dickinson and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 2. Global Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 3. Global Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 4. Global Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 5. Global Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 6. Global Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 7. Global Cancer Diagnostics Market Share, By Region, In USD Billion, 2016-2030F
  • Figure 8. North America Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 9. North America Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 10. North America Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 11. North America Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 12. North America Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 13. North America Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 14. North America Cancer Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 15. United States Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 16. United States Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 17. United States Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 18. United States Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 19. United States Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 20. United States Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 21. Canada Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 22. Canada Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 23. Canada Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 24. Canada Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 25. Canada Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 26. Canada Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 27. Mexico Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 28. Mexico Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 29. Mexico Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 30. Mexico Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 31. Mexico Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 32. Mexico Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 33. Europe Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 34. Europe Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 35. Europe Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 36. Europe Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 37. Europe Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 38. Europe Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 39. Europe Cancer Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 40. Germany Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 41. Germany Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 42. Germany Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 43. Germany Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 44. Germany Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 45. Germany Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 46. France Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 47. France Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 48. France Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 49. France Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 50. France Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 51. France Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 52. Italy Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 53. Italy Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 54. Italy Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 55. Italy Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 56. Italy Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 57. Italy Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 58. United Kingdom Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 59. United Kingdom Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 60. United Kingdom Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 61. United Kingdom Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 62. United Kingdom Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 63. United Kingdom Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 64. Russia Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 65. Russia Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 66. Russia Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 67. Russia Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 68. Russia Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 69. Russia Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 70. Netherlands Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 71. Netherlands Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 72. Netherlands Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 73. Netherlands Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 74. Netherlands Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 75. Netherlands Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 76. Spain Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 77. Spain Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 78. Spain Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 79. Spain Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 80. Spain Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 81. Spain Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 82. Turkey Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 83. Turkey Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 84. Turkey Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 85. Turkey Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 86. Turkey Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 87. Turkey Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 88. Poland Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 89. Poland Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 90. Poland Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 91. Poland Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 92. Poland Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 93. Poland Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 94. South America Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 95. South America Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 96. South America Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 97. South America Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 98. South America Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 99. South America Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 100. South America Cancer Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 101. Brazil Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 102. Brazil Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 103. Brazil Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 104. Brazil Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 105. Brazil Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 106. Brazil Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 107. Argentina Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 108. Argentina Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 109. Argentina Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 110. Argentina Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 111. Argentina Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 112. Argentina Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 113. Asia-Pacific Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 114. Asia-Pacific Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 115. Asia-Pacific Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 116. Asia-Pacific Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 117. Asia-Pacific Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 118. Asia-Pacific Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 119. Asia-Pacific Cancer Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 120. India Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 121. India Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 122. India Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 123. India Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 124. India Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 125. India Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 126. China Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 127. China Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 128. China Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 129. China Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 130. China Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 131. China Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 132. Japan Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 133. Japan Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 134. Japan Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 135. Japan Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 136. Japan Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 137. Japan Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 138. Australia Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 139. Australia Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 140. Australia Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 141. Australia Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 142. Australia Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 143. Australia Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 144. Vietnam Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 145. Vietnam Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 146. Vietnam Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 147. Vietnam Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 148. Vietnam Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 149. Vietnam Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 150. South Korea Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 151. South Korea Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 152. South Korea Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 153. South Korea Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 154. South Korea Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 155. South Korea Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 156. Indonesia Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 157. Indonesia Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 158. Indonesia Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 159. Indonesia Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 160. Indonesia Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 161. Indonesia Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 162. Philippines Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 163. Philippines Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 164. Philippines Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 165. Philippines Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 166. Philippines Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 167. Philippines Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 168. Middle East & Africa Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 169. Middle East & Africa Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 170. Middle East & Africa Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 171. Middle East & Africa Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 172. Middle East & Africa Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 173. Middle East & Africa Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 174. Middle East & Africa Cancer Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 175. Saudi Arabia Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 176. Saudi Arabia Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 177. Saudi Arabia Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 178. Saudi Arabia Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 179. Saudi Arabia Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 180. Saudi Arabia Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 181. UAE Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 182. UAE Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 183. UAE Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 184. UAE Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 185. UAE Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 186. UAE Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 187. South Africa Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 188. South Africa Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 189. South Africa Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 190. South Africa Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 191. South Africa Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 192. South Africa Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 193. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 194. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 195. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022